Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the renin-angiotensin system and inflammatory pathways. [PDF]
Front PharmacolFarrag SM +6 more
europepmc +1 more source
From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension. [PDF]
Clin HypertensPark JS, Sung KC, Rhee MY.
europepmc +1 more source
Pregnancy Outcome in a Patient With DADA2 Syndrome on Continued Adalimumab Therapy. [PDF]
Int J Rheum DisPridhivi B +5 more
europepmc +1 more source
A Simple and Sensitive LC-MS/MS Method for Simultaneous Quantification of Dasatinib and Erythromycin in Mice Plasma: Application to Preclinical Pharmacokinetic Study. [PDF]
Biomed ChromatogrKumar A +4 more
europepmc +1 more source
Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT. [PDF]
HypertensionAhn JC +24 more
europepmc +1 more source
Telmisartan protects male reproductive function by modulating biochemical, oxidative stress, apoptosis, and DNA integrity in cyclophosphamide-exposed rats. [PDF]
Toxicol RepKassid AA +3 more
europepmc +1 more source
Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors. [PDF]
Alzheimers DementLiu CH +5 more
europepmc +1 more source
Comparative effectiveness of telmisartan vs. other angiotensin receptor blockers in reducing hypertension-related cerebrovascular and cardiovascular events: a real-world retrospective study using the TriNetX network. [PDF]
Front Cardiovasc MedChen TY, Lin YC, Liu GY, Hung HC.
europepmc +1 more source
Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants. [PDF]
Naunyn Schmiedebergs Arch PharmacolGoh S, Huh KY, Lee S, Cho JY, Yu KS.
europepmc +1 more source